IDEXX Laboratories Inc (IDXX)vsInotiv Inc (NOTV)
IDXX
IDEXX Laboratories Inc
$562.16
-0.46%
HEALTHCARE · Cap: $44.24B
NOTV
Inotiv Inc
$0.09
-27.65%
HEALTHCARE · Cap: $5.79M
Smart Verdict
WallStSmart Research — data-driven comparison
IDEXX Laboratories Inc generates 776% more annual revenue ($4.45B vs $507.36M). IDXX leads profitability with a 24.6% profit margin vs -17.1%. IDXX earns a higher WallStSmart Score of 63/100 (C+).
IDXX
Buy63
out of 100
Grade: C+
NOTV
Avoid31
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-53.1%
Fair Value
$423.77
Current Price
$562.16
$138.39 premium
Intrinsic value data unavailable for NOTV.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Every $100 of equity generates 70 in profit
Strong operational efficiency at 31.8%
Safe zone — low bankruptcy risk
Keeps 25 of every $100 in revenue as profit
Reasonable price relative to book value
Areas to Watch
Expensive relative to growth rate
Premium valuation, high expectations priced in
Trading at 28.6x book value
0.0% earnings growth
Smaller company, higher risk/reward
Weak financial health signals
ROE of -74.1% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : IDXX
The strongest argument for IDXX centers on Return on Equity, Operating Margin, Altman Z-Score. Profitability is solid with margins at 24.6% and operating margin at 31.8%. Revenue growth of 14.3% demonstrates continued momentum.
Bull Case : NOTV
The strongest argument for NOTV centers on Price/Book.
Bear Case : IDXX
The primary concerns for IDXX are PEG Ratio, P/E Ratio, Price/Book. A P/E of 41.3x leaves little room for execution misses.
Bear Case : NOTV
The primary concerns for NOTV are EPS Growth, Market Cap, Piotroski F-Score. Debt-to-equity of 6.33 is elevated, increasing financial risk.
Key Dynamics to Monitor
IDXX profiles as a mature stock while NOTV is a turnaround play — different risk/reward profiles.
NOTV carries more volatility with a beta of 3.77 — expect wider price swings.
IDXX is growing revenue faster at 14.3% — sustainability is the question.
IDXX generates stronger free cash flow (234M), providing more financial flexibility.
Bottom Line
IDXX scores higher overall (63/100 vs 31/100), backed by strong 24.6% margins and 14.3% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
IDEXX Laboratories Inc
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
IDEXX Laboratories, Inc. is an American multinational corporation engaged in the development, manufacture, and distribution of products and services for the companion animal veterinary, livestock and poultry, water testing, and dairy markets.
Inotiv Inc
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
Inotiv, Inc. provides drug discovery and development services to the pharmaceutical, chemical, and medical device industries; and sells analytical instruments to the pharmaceutical development and contract research industries. The company is headquartered in West Lafayette, Indiana.
Compare with Other DIAGNOSTICS & RESEARCH Stocks
Want to dig deeper into these stocks?